114 related articles for article (PubMed ID: 23083827)
1. Hepatitis C virus drug resistance: implications for clinical management.
Wyles DL
Infect Dis Clin North Am; 2012 Dec; 26(4):967-78. PubMed ID: 23083827
[TBL] [Abstract][Full Text] [Related]
2. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
Matthews SJ; Lancaster JW
Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
[TBL] [Abstract][Full Text] [Related]
3. New developments in HCV therapy.
Kronenberger B; Zeuzem S
J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
[TBL] [Abstract][Full Text] [Related]
4. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J
J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
6. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
Welsch C; Jesudian A; Zeuzem S; Jacobson I
Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
[TBL] [Abstract][Full Text] [Related]
7. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
[TBL] [Abstract][Full Text] [Related]
8. Two years' persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy.
Colson P; Gérolami R
J Infect Dis; 2011 May; 203(9):1341-2; author reply 1342-3. PubMed ID: 21459820
[No Abstract] [Full Text] [Related]
9. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
Wyles DL
J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
[TBL] [Abstract][Full Text] [Related]
10. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
Trembling PM; Tanwar S; Dusheiko GM
Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
[TBL] [Abstract][Full Text] [Related]
11. Future of hepatitis C therapy: development of direct-acting antivirals.
Dore GJ; Matthews GV; Rockstroh J
Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
[TBL] [Abstract][Full Text] [Related]
12. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.
Barnard RJ; Howe JA; Ogert RA; Zeuzem S; Poordad F; Gordon SC; Ralston R; Tong X; Sniukiene V; Strizki J; Ryan D; Long J; Qiu P; Brass CA; Albrecht J; Burroughs M; Vuocolo S; Hazuda DJ
Virology; 2013 Sep; 444(1-2):329-36. PubMed ID: 23876458
[TBL] [Abstract][Full Text] [Related]
13. [HCV protease inhibitors and drug resistance].
Pawłowska M; Olczak A
Przegl Epidemiol; 2012; 66(1):55-7. PubMed ID: 22708299
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
[TBL] [Abstract][Full Text] [Related]
15. Future directions in therapy for chronic hepatitis C.
Jensen DM; Ascione A
Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
[TBL] [Abstract][Full Text] [Related]
16. [Antiviral treatment of chronic hepatitis C].
Berger A
Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
[TBL] [Abstract][Full Text] [Related]
17. Directly acting antivirals against hepatitis C virus.
Soriano V; Vispo E; Poveda E; Labarga P; Martin-Carbonero L; Fernandez-Montero JV; Barreiro P
J Antimicrob Chemother; 2011 Aug; 66(8):1673-86. PubMed ID: 21652618
[TBL] [Abstract][Full Text] [Related]
18. Targets for antiviral therapy of hepatitis C.
Rupp D; Bartenschlager R
Semin Liver Dis; 2014 Feb; 34(1):9-21. PubMed ID: 24782254
[TBL] [Abstract][Full Text] [Related]
19. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
Sullivan JC; De Meyer S; Bartels DJ; Dierynck I; Zhang EZ; Spanks J; Tigges AM; Ghys A; Dorrian J; Adda N; Martin EC; Beumont M; Jacobson IM; Sherman KE; Zeuzem S; Picchio G; Kieffer TL
Clin Infect Dis; 2013 Jul; 57(2):221-9. PubMed ID: 23575197
[TBL] [Abstract][Full Text] [Related]
20. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]